Skyfall And MorphoSys Announces CD38 Antibody (TJ202/MOR202) licensed by China's State Drug Administration clinical trial

recently, Tianyuan Biotech (Shanghai) LimitedCompany(http://("Tianyuan Bio") and Germany's MorphoSys Corporation announced that human source monoclonal CD38 antibody (TJ202/MOR202) was approved by China's NationalDrug(http://The Administration of Clinical and Phase III ClinicalTrial(http://About TJ202/MOR202
TJ202/MOR202 Developed by MorphoSys, Tianyuan Bio has exclusive development and commercialization interests in the mainland, Hong Kong, Macau and TaiwanTJ202/MOR202 is a human-source monoclonal antibody developed exclusively by MorphoSys using HuCAL technologyTJ202/MOR202 targets the surface CD38 antigen of multiple myeloma, which belongs to the antigen expressed equally equally on the surface of malignant plasma cellsThe mechanism of action of TJ202/MOR202 is to kill CD38-positive tumor cells by antibody-dependent cytotoxicity and antibody-dependent cellsBut there is no involvement in the cytotoxic effects of complement dependence (CDC)Studies have shown that CD38 antibodies also have the potential to treat other cancers and autoimmune diseases 　　Under the license agreement signed in November 2017 between Skyfall And MorphoSys, Skyfall Bio has exclusive development and commercialization rights in Chinese mainland, Taiwan, Hong Kong and Macau 　　Tianyuan Bio has launched a number of clinical trials of TJ202/MOR202 in Taiwan 　　Phase II clinical trials are designed to evaluate the efficacy and safety of TJ202/MOR202 as a three-line treatment regimen in patients with recurrent or refractory myeloma in March 2019; The safety and efficacy of the combination of LEN, dycemisone (DEX) and LEN and DEX drugs will be conducted in April 2019 in patients with relapse or difficulty in treating multiple myeloma after receiving at least one-line treatment